The FDA decision on EM-100, an over-the-counter preservative-free formulation of ketotifen ophthalmic solution, proposed for the treatment of ocular itching associated with allergic conjunctivitis is expected on August 10, 2020.Developed by Eton Pharmaceuticals Inc. (ETON), EM-100 was out-licensed to Bausch Health Companies Inc. (BHC) in 2019.This is EM-100’s second go-around with the FDA. The eye drop was denied regulatory approval in July 2019.BHC closed Friday’s (Jul.24, 2020) trading at $17.05, up 0.18%.